Melanoma / Skin Clinical Trials
Delivering quality care through clinical trials
Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.
ECOG-ACRIN - EA6141
Study Phase: Phase II/III, Drug
Condition(s): Stage III or IV melanoma
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
ClinicalTrials.gov NCT ID: NCT02339571
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Regeneron - R3767-ONC-22122
Study Phase: Phase III - Drug
Condition(s): Unresectable or metastatic melanoma
A Phase 3 Study Of Fixed Dose Combinations Of Fianlimab And Cemiplimab Versus Relatlimab And Nivolumab In Participants With Unresectable Or Metastatic Melanoma
ClinicalTrials.gov NCT ID: NCT06246916
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Iovance - IOV-MEL-301
Study Phase: Phase III - Drug
Condition(s): Unresectable or metastatic melanoma
A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
ClinicalTrials.gov NCT ID: NCT 05727904
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
U of Kentucky - UKY-MCC-20-MEL-11-PMC
Study Phase: Phase I - Drug
Condition(s): BRAF mutated metastatic melanoma
A Phase I Study of Nilotinib in Combination with Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma after Progression on BRAF/MEK Inhibition
ClinicalTrials.gov NCT ID: NCT04903119
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
